Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) at Fort Sam Houston Texas to explore the potential effects of OBI’s proprietary perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis. This CRADA has been initiated to complement ongoing research and development work funded previously by a Department of Defense grant to broaden the safety profile of the use of perfluorocarbon-based emulsions to treat patients with traumatic brain injury – an indication for which OBI is conducting Phase II clinical trials overseas.
Although a known response to perfluorocarbon-based emulsion products is the transient decline in circulating platelet counts, the mechanism by which this phenomenon occurs is poorly understood and its impact on overall coagulation pathways and clinical outcomes remains the subject of debate. Recently completed
studies using blood from normal healthy human volunteers at the Children’s Hospital in Boston have demonstrated that Oxycyte has little effect on the activation and function of platelets. The research being conducted under the present CRADA will investigate whether Oxycyte alters platelet activation, aggregation or adhesion in a model of systemic inflammation. Researchers will conduct
evaluations of platelet activity and whole blood clotting functions. Changes in the structural and functional properties of platelets will be evaluated including receptor expression and distribution, and aggregation in response to agonists. This work will be part of a larger study to determine the biodistribution of platelets following Oxycyte administration in this model. The company has undertaken this extensive preclinical program to address concerns that the U.S. FDA has expressed regarding perfluorocarbon-based emulsions.
“This work is important in terms of helping us better understand the mechanism surrounding platelet count declines in response to Oxycyte administration and we believe it will go a long way towards allaying the concerns the FDA has around the use of perfluorocarbon-based drugs and treatments, in general,” said Michael Jebsen, President and Chief Financial Officer of OBI. “We are pleased to be working with the highly respected Institute of Surgical Research at Fort Sam Houston. Their scientists have a strong working relationship with the Texas Biomedical Research Institute where other critical Oxycyte preclinical studies are currently underway. Based on the preliminary findings of a number of our ongoing studies in platelet function and immunocompetence, we believe we are compiling the data necessary to move Oxycyte back into clinical trials in the U.S. in the future.”